Our work on tuberculosis is led by colleagues at HE2RO.  For more information, please visit Information on the national TB cohort can be found at

Publications and other documents

Benade M, Long LC, Meyer-Rath G, Miot J, Evans D, Tucker JM, Moultrie H, Rosen S. Reduction in initiations of tuberculosis treatment in South Africa during the COVID pandemic. PLOS Global Public Health 2022; 2(10): e0000559.

Evans D, van Rensburg C, Govathson C, Ivanova O, Riess F, Siroka A, Sillah AK, Ntinginya NE, Jani I, Sathar F, Rosen S, Sanne I, Rachow A, Lonnruth K. Adaptation of WHO’s generic tuberculosis patient cost instrument for a longitudinal study in Africa. Global Health Action 2021; 14: 1865625.

Masuku SD, Berhanu R, Van Rensburg C, Ndjeka N, Rosen S, Long L, Evans D, Nichols BE. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis. Int J Tuberc Lung Dis. 2020 Apr 1; 24(4):376-382.

Jamieson L , Evans D, Berhanu R, Ismail N, Aucock S, Wallengren K, Long L. Data quality of drug-resistant tuberculosis and antiretroviral therapy electronic registers in South Africa. BMC Public Health 2019; 19: 1638.

Berry KM, Rodriguez CA, Berhanu RH, Ismail N, Mvusi L, Long L, Evans D. Treatment outcomes among children, adolescents, and adults on treatment for tuberculosis in two metropolitan municipalities in Gauteng Province, South Africa. BMC Public Health. 2019 Jul 22;19(1):973.

Van Rensburg C, Berhanu R, Hirasen K, Evans D, Rosen S, Long L. Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa. PLoS One 2019; 14(6): e0217820.

Sineke T, Evans D, Schnippel K, van Aswegen H, Berhanu R, Musakwa N, Lonnmark E, Long L, Rosen S. The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. Health and QOL Outcomes 2019; 17:94.

Evans D, SinekeT, Schnippe K, Berhanu R, Govathson C, Black A, Long L, Rosen S. Impact of Xpert MTB/RIF on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa. BMC Health Serv Res 2018;18:973.

Hirasen K, Berhanu R, Evans D, Rosen S, Sanne I, Long L. High rates of death and loss to follow-up by 12 months of rifampicin resistant TB treatment in South Africa. PloS One 2018; 13: e0205463.

Budgell E, Evans D, Mohamed R, Ive P, Long L, Rosen S. The costs and outcomes of paediatric tuberculosis treatment at primary health clinics in Johannesburg, South Africa. S Afr Med J 2018;108:423-431.

Evans D, Schippel K, Govathson C, Sineke T, Black A, Long L, Berhanu R, Rosen S. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa. PLOS One 2017; 12(7): e0181238.

Berhanu R, Schnippel K, Mohr E, Hirasen K, Evans D, Rosen S, Sanne I. Early outcomes of decentralized care for rifampicin-resistant tuberculosis in Johannesburg, South Africa. PLoS One 2016;11: e0164974.